Chemkart India IPO Fund Use: Capex on Track, Minor GCP Spending Variance

Chemkart India Ltd has filed its Q4 FY26 Monitoring Agency Report, offering an update on its Initial Public Offering (IPO) fund utilization. The report details how the company has deployed capital towards its manufacturing expansion and debt reduction efforts, while also highlighting a minor variance in General Corporate Purpose (GCP) spending.

Key Takeaways

• Manufacturing facility capital expenditure (capex) deployment is underway.
• IPO funds allocated for debt repayment have been fully used.
• A small spending variance is noted for General Corporate Purpose (GCP) funds.

Q4 FY26 IPO Fund Utilization

In its Monitoring Agency Report for the quarter ending March 31, 2026, Chemkart India detailed the utilization of the ₹80.08 crore raised through its IPO.

Capital expenditure towards the manufacturing facility saw ₹3.12 crore deployed during the quarter, bringing the total utilization for this purpose to ₹4.57 crore.

The company has fully utilized the ₹20.00 crore earmarked for repaying borrowings.

Total utilization for issue expenses reached ₹9.08 crore.

A specific point of attention is the utilization of funds for General Corporate Purpose (GCP). The offer document indicated ₹0.00 utilized, but the progress report states ₹0.46 crore had been spent, resulting in an unutilized balance of ₹-0.19 crore for GCP.

Why This Update is Important

This report offers investors transparency into how Chemkart India is deploying its IPO capital, confirming adherence to key objectives like expanding manufacturing capacity and reducing debt.

The noted variance in GCP fund utilization requires further clarification from the company regarding the precise use of these funds.

Company and Industry Background

Chemkart India's IPO was launched to finance manufacturing enhancements and lower outstanding debt. The company operates in the pharmaceutical intermediates and specialty chemicals sector, a field requiring consistent infrastructure investment.

Competitors like Ami Organics Ltd and Tatva Chintan Pharma Chem Ltd also typically invest heavily in capacity expansion, often using raised capital to boost production capabilities.

Looking Ahead

The expansion of the manufacturing facility is progressing as planned. The successful repayment of borrowings using IPO funds marks a key achievement.

Investors will be looking for the company's formal explanation regarding the GCP spending variance.

Continued monitoring will focus on the operational progress of the expanded facility and future capital allocation strategies.